ライフサイエンスコーパス: hydrochlorothiazide

1 eived either 50 mg of atenolol or 12.5 mg of hydrochlorothiazide.

2 g trandolapril; and 3430 (43.7%) were taking hydrochlorothiazide.

3 and 1 was the combination of triamterene and hydrochlorothiazide.

4 and equally reduced with both isradipine and hydrochlorothiazide.

5 eceived chlorthalidone and 9786 who received hydrochlorothiazide.

6 er-related deaths than patients who received hydrochlorothiazide.

7 is no evidence to prefer chlorthalidone over hydrochlorothiazide.

8 determined at baseline and after 9 weeks of hydrochlorothiazide.

9 as it is superior to normally used doses of hydrochlorothiazide.

10 adverse cardiovascular events or deaths than hydrochlorothiazide.

11 lus amlodipine compared with benazepril plus hydrochlorothiazide.

12 enazepril plus amlodipine or benazepril plus hydrochlorothiazide.

13 icipants were first prescribed polypill one (hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin

14 inhibitor/angiotensin receptor blocker, and hydrochlorothiazide 12.5 mg/day, followed by the sequent

15 At week 8, hydrochlorothiazide 12.5 to 25 mg and/or amlodipine 10 m

16 cebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo.

17 g per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) was associated wit

18 , amlodipine (2.5 mg), losartan (25 mg), and hydrochlorothiazide (12.5 mg).

19 ne (5 mg; n=5744) or benazepril (20 mg) plus hydrochlorothiazide (12.5 mg; n=5762), orally once daily

20 ce daily doses of isradipine (2.5-5.0 mg) or hydrochlorothiazide (12.5-25 mg).

21 ining 5 mg ramipril, 50 mg atenolol, 12.5 mg hydrochlorothiazide, 20 mg simvastatin, and 100 mg aspir

22 GITS) formulation (n=3157), or co-amilozide (hydrochlorothiazide 25 mg [corrected] plus amiloride 2.5

23 office blood pressure (AOBP) >140/90 mm Hg; hydrochlorothiazide 25 mg QD was added after 1 month if

24 y, followed by the sequential uptitration of hydrochlorothiazide (25 mg/day) and amlodipine (10 mg/da

25 Hydrochlorothiazide, 25 mg twice daily, for a mean (+/-

26 dralazine 7.5 mg/d, reserpine 0.15 mg/d, and hydrochlorothiazide 3 mg/d [HRH]) during weeks 7 through

27 en-label crossover trial comparing amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodi

28 egimen of 5 mg of amlodipine plus 12.5 mg of hydrochlorothiazide, 5 mg of amlodipine plus 4 mg of per

29 atients required supplemental treatment with hydrochlorothiazide (59% versus 34%, P<0.001) but not at

30 ose (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiazide 6.25 mg, and atenolol 12.5 mg).

31 lodipine, 189 of 561, 33.7%; benazepril plus hydrochlorothiazide, 85 of 532, 16.0%).

32 the COER verapamil (99/277) and atenolol or hydrochlorothiazide (88/274) groups; HR, 1.15 (95% CI, 0

33 es were 82%, 78%, and 14%, respectively, for hydrochlorothiazide; 88%, 67%, and 40%, respectively, fo

34 Hydrochlorothiazide, a blocker of the Na(+)-Cl(-) cotran

35 s, and bone mineral density before and after hydrochlorothiazide administration.

36 lorothiazide, or 5 mg amiloride plus 12.5 mg hydrochlorothiazide; all doses were doubled after 12 wee

37 Moreover, hydrochlorothiazide, an NCC-blocking drug, reversed tacr

38 ups, and mean SBP decreased by 19.5 mm Hg in hydrochlorothiazide and 16.0 mm Hg in isradipine (P=.002

39 Open-label hydrochlorothiazide and a dihydropyridine calcium antago

40 while MSNA responses were different between hydrochlorothiazide and aliskiren (P = 0.006 pre/post x

41 ance test (OGTT), compared first between the hydrochlorothiazide and amiloride groups, and then betwe

42 l or long-acting nifedipine, plus adjunctive hydrochlorothiazide and atenolol when needed to control

43 rates were similar with both benazepril and hydrochlorothiazide and benazepril and amlodipine, but r

44 e and amiloride groups, and then between the hydrochlorothiazide and combination groups.

45 enhanced photolysis of some compounds (e.g., hydrochlorothiazide and diclofenac) while reducing the b

46 tihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed fo

47 Mineral supplements, hydrochlorothiazide and potassium-sparing agents, beta-b

48 Hydrochlorothiazide and prazosin were best in low- and m

49 between the group receiving amlodipine plus hydrochlorothiazide and the group receiving amlodipine p

50 at 6 months, those receiving amlodipine plus hydrochlorothiazide and those receiving amlodipine plus

51 mediate release compartment with aspirin and hydrochlorothiazide and three sustained release compartm

52 ho were newly treated with chlorthalidone or hydrochlorothiazide and were not hospitalized for heart

53 85% of the subjects did not receive hydrochlorothiazide and were treated with firibastat alo

54 er, 1 was the combination of triamterene and hydrochlorothiazide, and 1 an alpha-blocker.

55 of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo d

56 were randomly assigned to amiloride, 146 to hydrochlorothiazide, and 150 to the combination group.

57 dequate blood pressure control on captopril, hydrochlorothiazide, and atenolol show a reduction of LV

58 de, lisinopril vs amlodipine, candesartan vs hydrochlorothiazide, and candesartan vs amlodipine.

59 nt polypill including aspirin, atorvastatin, hydrochlorothiazide, and either enalapril or valsartan f

60 ndividually complexed with the thiazide drug hydrochlorothiazide, and two thiazide-like drugs chlorth

61 ven a pill containing aspirin, atorvastatin, hydrochlorothiazide, and valsartan (polypill).

62 re taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide; and 4113 (52.4%) were taking trando

63 il) or beta-blocker/diuretic-based (atenolol/hydrochlorothiazide) antihypertensive care strategy.

64 Calcium channel blockers and hydrochlorothiazide are important causes of pruritic ski

65 osartan (n = 660) or atenolol (n = 666) with hydrochlorothiazide as the second agent in both arms, fo

66 Affairs health system and had been receiving hydrochlorothiazide at a daily dose of 25 or 50 mg to co

67 candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day or plac

68 candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day was not

69 calcium-containing kidney stones to receive hydrochlorothiazide at a dose of 12.5 mg, 25 mg, or 50 m

70 At baseline, hydrochlorothiazide at a dose of 25 mg per day had been

71 Attenuation rate constants of hydrochlorothiazide at different field sites from this s

72 ril was more effective than perindopril plus hydrochlorothiazide at lowering blood pressure at 6 mont

73 Chlorthalidone was not superior to hydrochlorothiazide at preventing kidney outcomes (369 o

74 The combination of amiloride with hydrochlorothiazide, at doses equipotent on blood pressu

75 domization to 1 of 6 antihypertensive drugs: hydrochlorothiazide, atenolol, captopril, clonidine, dil

76 eft atrial size decreased significantly with hydrochlorothiazide, atenolol, clonidine, and diltiazem

77 enazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H).

78 was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD p

79 Hydrochlorothiazide (BCS class IV drug) was chosen as th

80 essure than those receiving perindopril plus hydrochlorothiazide (between-group difference in the cha

81 phisms tested, that has been associated with hydrochlorothiazide BP response.

82 The genetic score of the hydrochlorothiazide BP-lowering alleles was associated w

83 +/- 3.3-mm reduction of LV cavity size with hydrochlorothiazide but no reduction with isradipine.

84 de derivatives (IDRA-21, hydroflumethiazide, hydrochlorothiazide, chlorothiazide, trichlormethiazide,

85 e combination was superior to the benazepril-hydrochlorothiazide combination in reducing cardiovascul

86 ignificantly higher in 25 good responders to hydrochlorothiazide compared with 25 poor responders (P=

87 Diuretic challenge tests with furosemide or hydrochlorothiazide confirmed reduced NKCC2 and NCC acti

88 As expected, atenolol and hydrochlorothiazide correlated positively with median ag

89 r, the natriuretic response to furosemide or hydrochlorothiazide did not differ between control and e

90 There was no relation between the hydrochlorothiazide dose and the occurrence of a primary

91 ars or older who initiated chlorthalidone or hydrochlorothiazide during this period.

92 enhanced removal of atorvastatin-diclofenac-hydrochlorothiazide (during the whole treatment) and ran

93 pril, or 4 mg of perindopril plus 12.5 mg of hydrochlorothiazide for 2 months.

94 ces were observed between chlorthalidone and hydrochlorothiazide for dialysis or kidney transplantati

95 Chlorthalidone was not superior to hydrochlorothiazide for kidney outcomes but was associat

96 The superior efficacy of hydrochlorothiazide for LV mass reduction is associated

97 Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiov

98 clinical trial comparing chlorthalidone and hydrochlorothiazide for the treatment of hypertension, w

99 gests that chlorthalidone may be superior to hydrochlorothiazide for the treatment of hypertension.

100 93) and in the combination group than in the hydrochlorothiazide group (-0.42 mmol/L [-0.84 to -0.004

101 ipine group (9.6%) and 679 in the benazepril-hydrochlorothiazide group (11.8%), representing an absol

102 gher in the chlorthalidone group than in the hydrochlorothiazide group (6.0% vs. 4.4%, P<0.001).

103 (81.6% to 89.7%) except men in the high-dose hydrochlorothiazide group (60.5%).

104 alidone group (702 patients [10.4%]) and the hydrochlorothiazide group (675 patients [10.0%]) (hazard

105 e COER verapamil group vs 365 in atenolol or hydrochlorothiazide group (hazard ratio [HR], 1.02; 95%

106 pared with 215 (3.7%) in the benazepril plus hydrochlorothiazide group (HR 0.52, 0.41-0.65, p<0.0001)

107 tly lower in the amiloride group than in the hydrochlorothiazide group (mean difference -0.55 mmol/L

108 roup (n = 118) compared with the atenolol or hydrochlorothiazide group (n = 79) (HR, 1.54 [95% CI, 1.

109 +/- 41 g lower than that at baseline in the hydrochlorothiazide group (p = 0.003) but only 7 +/- 50

110 p was significantly greater than that in the hydrochlorothiazide group (p=0.0068).

111 , in 62 of 105 patients (59%) in the 12.5-mg hydrochlorothiazide group (rate ratio vs. placebo, 1.33;

112 oint (95% CI, -0.12 to 1.71) for the 12.5-mg hydrochlorothiazide group and 0.92 percentage point (CI,

113 pine was significantly greater for the 25-mg hydrochlorothiazide group at 6 months (intergroup differ

114 on were more frequent in the benazepril plus hydrochlorothiazide group than in the benazepril plus am

115 ticipants in the amiloride group, 134 in the hydrochlorothiazide group, and 133 in the combination gr

116 for partcipants assigned to the atenolol or hydrochlorothiazide group.

117 amlodipine group than in the benazepril plus hydrochlorothiazide group.

118 group and 132.5/74.4 mm Hg in the benazepril-hydrochlorothiazide group.

119 ffer significantly between the amiloride and hydrochlorothiazide groups, but the fall in blood pressu

120 ges in intracellular Ca2+ concentration, but hydrochlorothiazide had no effect.

121 arbonate or the carbonic anhydrase inhibitor hydrochlorothiazide had partial restoration of arterial

122 Animals given the hydrochlorothiazide had the highest urinary volume, but

123 d to add-on therapy of spironolactone 25 mg, hydrochlorothiazide (HCTZ) 12.5 mg, or placebo for 6 mon

124 to evaluate the antihypertensive efficacy of hydrochlorothiazide (HCTZ) by ambulatory blood pressure

125 Chlorthalidone (CTD) is more potent than hydrochlorothiazide (HCTZ) in reducing blood pressure (B

126 Hydrochlorothiazide (HCTZ) in the 12.5-mg dose remains t

127 from 25 responders and 25 non-responders to hydrochlorothiazide (HCTZ) or chlorthalidone.

128 ts with acute heart failure, the addition of hydrochlorothiazide (HCTZ) to furosemide increased the d

129 ith a decrease in systolic BP in response to hydrochlorothiazide (HCTZ).

130 sive drugs (TRX; reserpine, hydralazine, and hydrochlorothiazide in drinking water; SP+TRX, n = 7) or

131 on, support first-line use of amiloride plus hydrochlorothiazide in hypertensive patients who need tr

132 s amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity

133 Hydrochlorothiazide increases urine volume without enhan

134 phosphorylated NCC expression and augmented hydrochlorothiazide-induced natriuresis; high sodium int

135 on of diastolic BP, 6 months of therapy with hydrochlorothiazide is associated with a substantial red

136 patients receiving isradipine compared with hydrochlorothiazide is of concern and should be studied

137 pecifically for the choices of lisinopril vs hydrochlorothiazide, lisinopril vs amlodipine, candesart

138 tertile of pretreatment LV mass treated with hydrochlorothiazide (mean, -42.9; 95% confidence limits,

139 f these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hypertensive part

140 inhibitor, aliskiren (n = 7), or a diuretic, hydrochlorothiazide (n = 7), for 6 months.

141 sudden death) in isradipine (n=25; 5.65%) vs hydrochlorothiazide (n=14; 3.17%) (P=.07), and a signifi

142 bypass graft) in isradipine (n=40; 9.05%) vs hydrochlorothiazide (n=23; 5.22%) (P=.02).

143 epril plus amlodipine, n=70; benazepril plus hydrochlorothiazide, n=73).

144 Attenuation of amisulpride, flufenamic acid, hydrochlorothiazide, naproxen, and xipamide can be quant

145 Highest stability was estimated for hydrochlorothiazide on all flowpaths.

146 iffer substantially among patients receiving hydrochlorothiazide once daily at a dose of 12.5 mg, 25

147 while upright aldosterone was greater after hydrochlorothiazide only (P = 0.002).

148 e-pill combinations of either benazepril and hydrochlorothiazide or benazepril and amlodipine.

149 a thiazide or thiazidelike diuretic such as hydrochlorothiazide or chlorthalidone, an angiotensin-co

150 n sub-Saharan Africa, amlodipine plus either hydrochlorothiazide or perindopril was more effective th

151 t randomized 13 523 participants to continue hydrochlorothiazide or switch to chlorthalidone.

152 dose of 25 or 50 mg to continue therapy with hydrochlorothiazide or to switch to chlorthalidone at a

153 g simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide or to usual care (n=1002).

154 ent strategy on the basis of either atenolol/hydrochlorothiazide or verapamil-SR (sustained release)/

155 ith starting doses of 10 mg amiloride, 25 mg hydrochlorothiazide, or 5 mg amiloride plus 12.5 mg hydr

156 h atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked tria

157 h atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, or prazosin in a double-masked tria

158 n of mean maximum IMT between isradipine and hydrochlorothiazide over 3 years (P=.68).

159 concentration in lake water was observed for hydrochlorothiazide (over a factor of 10), and this was

160 decreased by 43 +/- 45 g (mean +/- SD) with hydrochlorothiazide (p < 0.001) but only by 11 +/- 48 g

161 mm Hg at 3 and 6 months, respectively, with hydrochlorothiazide (p = 0.003, between-group comparison

162 ring alleles was associated with response to hydrochlorothiazide (P=0.0006 for systolic BP; P=0.0003

163 or chlorthalidone vs 939 of 4518 [20.8%] for hydrochlorothiazide; P = .59) or acute kidney injury req

164 [6.4%] for chlorthalidone vs 379 [6.2%] for hydrochlorothiazide; P = .63) between groups.

165 ent to one of three study groups: 12.5 mg of hydrochlorothiazide per day, 25 mg of hydrochlorothiazid

166 mg of hydrochlorothiazide per day, 25 mg of hydrochlorothiazide per day, or placebo.

167 with those prescribed 12.5, 25, or 50 mg of hydrochlorothiazide per day, the former were more likely

168 In healthy older adults, low-dose hydrochlorothiazide preserves bone mineral density at th

169 malization by treatment with hydralazine and hydrochlorothiazide prevented angiotensin II-induced vas

170 vents per 100 person-years of follow-up, and hydrochlorothiazide recipients experienced 3.4 events pe

171 orthalidone recipient was matched to up to 2 hydrochlorothiazide recipients on the basis of age, sex,

172 ) being treated with a hydralazine-reserpine-hydrochlorothiazide regimen.

173 Hydrochlorothiazide resolved hypercalciuria and increase

174 , (2) RSG + furosemide (RSG+FRUS), (3) RSG + hydrochlorothiazide (RSG+HCTZ), (4) RSG + spironolactone

175 considered in preference to benazepril plus hydrochlorothiazide since it slows progression of nephro

176 were more common among patients who received hydrochlorothiazide than among those who received placeb

177 -3.3 mm) in left atrial size at 2 years with hydrochlorothiazide than with any other drug.

178 wever, reduction at 2 years was greater with hydrochlorothiazide than with captopril or prazosin.

179 ate, climbazole, diclofenac, furosemide, and hydrochlorothiazide), the measured persistence was lower

180 In patients allocated benazepril and hydrochlorothiazide, the primary endpoint (per 1000 pati

181 NDINGS: In patients allocated benazepril and hydrochlorothiazide, the primary endpoint (per 1000 pati

182 es were randomized to isradipine (n = 89) or hydrochlorothiazide therapy (n = 45).

183 candesartan [angiotensin-receptor blocker], hydrochlorothiazide [thiazide], and amlodipine [calcium

184 diltiazem for older black men, from 70% for hydrochlorothiazide to 92% for atenolol for younger whit

185 olol for younger white men, and from 84% for hydrochlorothiazide to 95% for diltiazem for older white

186 the following conditions: normal, hydrated, hydrochlorothiazide treated and phlorizin treated.

187 supine and upright MSNA became greater after hydrochlorothiazide treatment (supine, 72 +/- 18 post vs

188 Hydrochlorothiazide treatment in hypercalciuric and oste

189 us trandolapril) vs B-blocker (atenolol plus hydrochlorothiazide) treatment strategy.

190 d the associations between chlorthalidone vs hydrochlorothiazide use and the outcomes of interest ove

191 h a higher risk of hypokalemia compared with hydrochlorothiazide use, which was more pronounced among

192 2]) across all eGFR categories compared with hydrochlorothiazide use.

193 scular events, and hypokalemia compared with hydrochlorothiazide use.

194 lorthalidone users were matched 1:4 with new hydrochlorothiazide users by a high-dimensional propensi

195 le was associated with better BP response to hydrochlorothiazide versus noncarriers (Delta systolic B

196 the choices of lisinopril vs candesartan and hydrochlorothiazide vs amlodipine.

197 Trandolapril and/or hydrochlorothiazide was administered to achieve blood pr

198 Without adjustment for covariates, only hydrochlorothiazide was associated with decreases in lef

199 Hydrochlorothiazide was associated with greater overall

200 cidence of hypokalemia for chlorthalidone vs hydrochlorothiazide was observed (545 [8.9%] vs 426 [6.9

201 Greater LV mass reduction with hydrochlorothiazide was related to a 2.8 +/- 3.3-mm redu

202 ystem blocker with amlodipine, compared with hydrochlorothiazide, was superior in reducing cardiovasc

203 s or older with hypertension who were taking hydrochlorothiazide were included.

204 Trandolapril and hydrochlorothiazide were used as added agents.

205 dies may predict BP response to atenolol and hydrochlorothiazide when assessed through risk scoring.

206 ad a history of hypertension controlled with hydrochlorothiazide, without any other cardiovascular ri